Engineering Redox-Active
Therapeutics for
Controlled Clinical Translation
Transforming lawsone (2-hydroxy-1,4-naphthoquinone) into a clinically viable, precision-controlled therapeutic system through advanced engineering of stability, delivery, and redox behaviour.
Redox-active quinone scaffold — 2-hydroxy-1,4-naphthoquinone
Antimicrobial, anti-inflammatory, antifibrotic, and cell-modulating
Stability engineering, controlled release, and redox behaviour modulation
Multi-indication, combination-capable, SynapTx-integrated
Overview
A platform built not around
a molecule — but a system
The Lawsone-Based Therapeutic Platform at Dhee Lifesciences is focused on transforming lawsone into a clinically viable, precision-controlled therapeutic system. Despite its strong biological profile, lawsone has historically remained translationally inaccessible due to intrinsic chemical and pharmacokinetic limitations.
At Dhee Lifesciences, we convert a reactive molecule into a predictable, exposure-defined therapeutic platform — engineering each constraint into a controllable parameter.
“Reactive molecules require engineered control — not suppression — to become therapeutically viable.”
The Problem
The translational barriers
constraining lawsone
The therapeutic potential of lawsone has long been recognised, yet its development has been constrained by a set of fundamental challenges inherent to quinone chemistry:
Consequences in biological systems
Our Approach
Five platform capabilities
converting reactivity into precision
We design integrated delivery and activation systems that convert lawsone into a precision therapeutic modality. Each capability addresses a distinct failure mode of conventional quinone development.
Capability 01
Structural Stabilisation
- Encapsulation of quinone systems within protective carriers
- Prevention of premature oxidation and degradation
- Preservation of functional integrity during storage and circulation
Capability 02
Controlled Release Architectures
- Tunable release kinetics (burst vs sustained vs depot)
- Site-specific delivery to target tissues (e.g., liver, wound bed)
- Reduction of systemic exposure and off-target effects
Capability 03
Redox Behaviour Modulation
- Engineering of electron transfer dynamics
- Controlled interaction with ROS and cellular redox systems
- Optimisation of therapeutic vs cytotoxic thresholds
Capability 04
Triggered Activation Systems
- pH-responsive activation in inflamed or infected tissues
- Enzyme-mediated release in disease microenvironments
- Activation driven by oxidative stress and fibrosis niches
Capability 05
Combination Reactive Platforms
- Integration with nitric oxide (NO) and HNO systems
- Synergistic antimicrobial and tissue-modulating effects
- Multi-mechanistic action in complex disease settings
Technical Focus
Five core technical
development domains
Our development efforts are concentrated across five engineering domains, each addressing a critical dimension of quinone-based drug delivery.
Quinone Stabilisation Systems
Advanced encapsulation strategies to preserve lawsone integrity and prevent premature degradation in biological environments.
Carrier-Based Delivery Architectures
Lipid, polymeric, and hybrid systems enabling targeted and controlled exposure at the therapeutic site.
Controlled-Release Platforms
Depot formulations and sustained-release systems for localised, prolonged therapeutic effect.
Redox-Modulating Formulations
Fine-tuning of oxidative and reductive behaviour to maximise therapeutic index and minimise cytotoxicity.
Triggered Activation Mechanisms
Responsive systems that activate only under disease-relevant conditions, enabling precision localised action.
Why it matters
“Unlike conventional drug development approaches, we do not optimise the molecule alone — we engineer the system in which the molecule operates.”
SynapTx Integration
A computational backbone
for rational design
Our SynapTx platform provides predictive intelligence across the full formulation design cycle, reducing experimental uncertainty and accelerating iteration.
SynapTx enables
Therapeutic Opportunity Areas
Four high-value
application domains
The lawsone platform addresses critical unmet needs across four therapeutic areas where controlled redox delivery and localised activation offer meaningful clinical advantage.
Wound Care & Tissue Repair
Localised antimicrobial and regenerative action in complex wound environments requiring sustained activity.
Anti-Infective & Antimicrobial
Broad-spectrum activity against bacterial and fungal pathogens, including biofilm-forming organisms.
Fibrosis & Inflammatory Disease
Direct stellate-cell reprogramming and YAP inhibition for liver fibrosis and beyond.
Combination Reactive Therapeutics
Integration with NO and HNO platforms for multi-mechanistic action in complex disease settings.
Collaboration Opportunity
Actively seeking
strategic partners
We are seeking scientific and strategic partners to co-develop lawsone-based systems across priority therapeutic areas.
Advanced wound care and regenerative medicine applications
Anti-infective and antimicrobial platform development
Fibrosis-targeted therapies, including liver and extra-hepatic disease
Combination reactive therapeutics integrating NO, HNO, and quinone systems
What we offer partners
Closing Statement
From reactive molecule to
predictable therapeutic system
By engineering stability, delivery, and redox control, we transform lawsone from a reactive molecule into a predictable therapeutic system — unlocking its true clinical potential across wound care, anti-infective, fibrotic, and combination therapeutic applications.
Discuss a Collaboration